Peptipedia
Growth HormoneFDA ApprovedFDA Approved

Tesamorelin

Also known as Egrifta, Egrifta WR, Egrifta SV, TH9507, Tesamorelin F8

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved)
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

2 mg daily (F8: 1.28 mg daily)

Frequency

Once daily

Duration

Indefinite for approved indication

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 2 mg daily (F8: 1.28 mg daily) via Subcutaneous injection, Once daily. Dose range: 1.28-2 mg daily. Duration: Indefinite for approved indication.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Once daily.

Mechanism of Action

A stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. Specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved).

Side Effects & Safety

Important Warnings

  • Increased diabetes risk
  • Rare anaphylaxis.
Injection site reactions
joint pain
peripheral edema
pain in extremities
muscle pain
increased diabetes risk
elevated blood glucose
allergic reactions including anaphylaxis

References

No references available.

Related Peptides

Browse all →
IpamorelinGrowth Hormone

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

View profile
CJC-1295Growth Hormone

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

View profile
GHRP-6Growth Hormone

One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite.

View profile